Selection of currently ongoing clinical pharmaceutical trials at the NCRC

Multiple Sclerosis studies / MOGAD:

Title

Link to the public  register

Recruitment
status

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis (HERCULES)

NCT04411641 finished
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive  multiple sclerosis (PERSEUS)

NCT04458051 active
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab as monotherapy or in addition to baseline therapy in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)

NCT05271409 active

A Randomized, double-blind, Placebo-controlled, multicenter Phase 3 pivotal study to evaluate the efficacy and safety of rozanolixizumab to treat adult patients with Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)

NCT05063162 active

 

Myasthenia gravis studies:

Titel

Link to the public register

Recruitment
status

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

NCT05403541 active
Evaluating the Long-Term Safety and Tolerability of Efgartigimod
PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis (ADAPTSC+)

NCT04818671 active
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis 

NCT04951622 active
A Phase 3B, Randomized, Open-label, Parallel-Group Trial to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis (ADAPT NXT)

NCT04980495 active
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096 active
A Phase 3, multinational, randomized, double-blind, placebo-controlled trial to examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis (NIMBLE) NCT05070858 active

 

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) studies:

Title

Link to the public register 

Recruitment
status

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

NCT05581199 active